Use of TNFα inhibitor for treatment of psoriatic arthritis
AssigneeAbbVie Biotechnology Ltd.
InventorsRebecca S. Hoffman, Mark Weinberg
Life of this patent
Estimating the term…
Abstract
The invention describes methods of treating erosive polyarthritis comprising administering a TNFα antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNFα antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
Claims9
A method of treatment of moderate to severe active psoriatic arthritis in adult patients, wherein each said patient has ≧3 swollen and ≧3 tender joints prior to the treatment and has failed NSAID therapy, comprising subcutaneously administering to each said patient 40 mg of adalimumab every other week, wherein 23% of said patients achieve 70% reduction in American College of Rheumatology (ACR) score at week 24 of the treatment.
A method for reducing or inhibiting symptoms in a patient with psoriatic arthritis, comprising subcutaneously administering to said patient 40 mg of adalimumab every other week.
Dependencies are inferred from the claim text.